Maruho Hatsujyo Innovations (MHI), the U.S. subsidiary of Maruho Co. Ltd, a Japanese healthcare company with subsidiaries in Europe and the U.S. with global sales of $800 million – has launched a new prototyping service that creates test products from 3D printing technology. For MHI’s clientele, the service makes available sample blister cavities nearly identical to final production, saving time and money compared with traditional metal tooling prototypes.
The new service’s calling card is speed: the technology provides blister prototypes in days rather than weeks, allowing companies to take a more expedient “try before they buy” approach to new or modified packaging platforms, including those being tested as part of stability studies. The dramatically reduced cost also provides leeway to test multiple blister formulations to determine which is most suitable for particular medicines, medical devices or other high-end products.
Maruho Hatsujyo Innovations